ETNB Stock Price, 89bio Inc Quote, Chart

Market Summary

USD9.18+0.10

Delayedas of 22 Apr 2024, 12:52 pm

1.10%

ETNB Alerts

1 major insider sales recently.

ETNB Stock Price

View Fullscreen

ETNB RSI Chart

ETNB Valuation

Market Cap

849.0M

Price/Earnings (Trailing)

-5.97

Price/Sales (Trailing)

545.28

EV/EBITDA

-4.18

Price/Free Cashflow

-6.57

ETNB Price/Sales (Trailing)

ETNB Profitability

EBT Margin

-6391.96%

Return on Equity

-26.51%

Return on Assets

-23.85%

Free Cashflow Yield

-15.22%

ETNB Fundamentals

ETNB Revenue

Revenue (TTM)

2.2M

ETNB Earnings

Earnings (TTM)

-142.2M

Earnings Growth (Yr)

-63.54%

Earnings Growth (Qtr)

-15.87%

Breaking Down ETNB Revenue

52 Week Range

9.1222.93

(Low)(High)

Last 7 days

-7.4%

Last 30 days

-19.7%

Last 90 days

-17.7%

Trailing 12 Months

-44.6%

How does ETNB drawdown profile look like?

ETNB Financial Health

Current Ratio

20.04

Debt/Equity

0.05

Debt/Cashflow

-5.21

ETNB Investor Care

Shares Dilution (1Y)

79.02%

Diluted EPS (TTM)

-2.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	652.0K	1.2M	1.7M	2.2M
2021	0	0	0	148.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of 89bio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	ra capital management, l.p.	acquired	7,500,000	5.325	1,408,450	-
Apr 01, 2024	palekar rohan	sold	-575,153	10.91	-52,718	chief executive officer
Apr 01, 2024	palekar rohan	acquired	48,250	1.93	25,000	chief executive officer
Mar 04, 2024	ra capital management, l.p.	bought	20,722,500	15.35	1,350,000	-
Feb 26, 2024	palekar rohan	sold	-48,172	10.76	-4,477	chief executive officer
Feb 17, 2024	mansbach harry h	sold (taxes)	-10,188	9.74	-1,046	chief medical officer
Feb 17, 2024	martins ryan	sold (taxes)	-7,577	9.74	-778	chief financial officer
Feb 17, 2024	le-nguyen quoc	sold (taxes)	-10,188	9.74	-1,046	see remarks
Feb 17, 2024	palekar rohan	sold (taxes)	-44,823	9.74	-4,602	chief executive officer
Feb 09, 2024	palekar rohan	sold (taxes)	-107,062	8.45	-12,670	chief executive officer

Which funds bought or sold ETNB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	9,000	-%
Apr 05, 2024	GAMMA Investing LLC	added	492	1,655	1,932	-%
Apr 05, 2024	CWM, LLC	unchanged	-	-	3,000	-%
Mar 27, 2024	NOMURA HOLDINGS INC	new	-	915,940	915,940	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	10.15	-42,026	164,870	-%
Mar 11, 2024	VANGUARD GROUP INC	added	22.17	-6,322,350	48,115,700	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	143	6,090,720	14,099,000	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	3.17	-120,805	355,519	-%
Feb 23, 2024	Chicago Partners Investment Group LLC	added	43.61	86,211	157,573	0.01%
Feb 20, 2024	Quarry LP	reduced	-88.24	-120,070	11,170	-%

Are Funds Buying or Selling ETNB?

Are funds buying ETNB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ETNB

No. of Funds

ETNB Alerts

1 major insider sales recently.

Unveiling 89bio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 06, 2024	ra capital management, l.p.	14.8%	14,254,298	SC 13D/A
Feb 14, 2024	deep track capital, lp	2.10%	2e+06	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	4.2%	3,973,784	SC 13G/A
Feb 14, 2024	cormorant asset management, lp	0.00%	0	SC 13G/A
Feb 14, 2024	rtw investments, lp	6.0%	5,578,931	SC 13G
Feb 13, 2024	suvretta capital management, llc	5.2%	4,888,434	SC 13G/A
Feb 12, 2024	janus henderson group plc	10.8%	10,081,258	SC 13G/A
Feb 12, 2024	janus henderson group plc	9.6%	8,915,141	SC 13G/A
Feb 07, 2024	adage capital partners gp, l.l.c.	4.48%	4,225,000	SC 13G/A
Jan 29, 2024	blackrock inc.	5.9%	5,454,196	SC 13G

Recent SEC filings of 89bio Inc

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	ARS	ARS
Apr 17, 2024	8-K	Current Report
Apr 17, 2024	DEF 14A	DEF 14A
Apr 17, 2024	DEFA14A	DEFA14A
Apr 15, 2024	4	Insider Trading
Apr 10, 2024	8-K	Current Report
Apr 03, 2024	4	Insider Trading
Apr 01, 2024	144	Notice of Insider Sale Intent
Mar 08, 2024	S-8	Employee Benefits Plan
Mar 06, 2024	SC 13D/A	13D - Major Acquisition

Peers (Alternatives to 89bio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	38.7B	6.8B	-1.66%	-28.18%	-8.22	5.66	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.2B	1.8B	-2.46%	-28.84%	-41.3	9.94	76.23%	61.08%
BMRN	16.7B	2.4B	4.57%	-8.46%	99.75	6.91	15.42%	18.43%
INCY	11.8B	3.7B	-10.11%	-29.11%	19.67	3.18	8.87%	75.42%
MID-CAP
APLS	5.7B	396.6M	-14.37%	-42.33%	-10.84	14.45	425.83%	18.94%
BBIO	4.4B	-	-13.59%	50.21%	-6.66	60.35	54.84%	-34.79%
AXSM	3.2B	270.6M	-13.81%	-4.67%	-13.45	11.89	440.80%	-27.84%
ACAD	2.8B	726.4M	-9.91%	-15.82%	-45.22	3.82	40.45%	71.62%
ARWR	2.8B	240.7M	-20.67%	-25.33%	-9.32	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-10.64%	-8.42%	24.94	4.47	85.90%	-14.05%
NVAX	558.4M	983.7M	-17.39%	-51.52%	-1.02	0.57	-50.36%	17.16%
CRBP	409.4M	881.7K	-0.38%	387.14%	-9.18	466.16	-77.61%	-5.33%
INO	226.2M	4.9M	-10.29%	-2.81%	-1.67	46.49	-54.97%	51.71%
IBIO	6.0M	2.1M	59.81%	33.59%	-0.22	2.14	-13.45%	66.37%

89bio Inc News

Latest updates

89bio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4
Operating Expenses	-6.2%	25,362,000	27,041,000	24,738,000	25,108,000	26,241,000
S&GA Expenses	30.0%	6,298,000	4,844,000	5,052,000	5,259,000	5,262,000
R&D Expenses	-14.1%	19,064,000	22,197,000	19,686,000	19,849,000	20,979,000
EBITDA Margin	25.6%	-46.22	-62.12	-90.51	-153	-604
Interest Expenses	1.9%	545,000	535,000	434,000	408,000	-
Income Taxes	700.0%	16,000	2,000	-	1,000	-
Earnings Before Taxes	8.3%	-24,586,000	-26,803,000	-25,054,000	-25,564,000	-26,435,000
EBT Margin	24.7%	-47.14	-62.56	-91.16	-154	-609
Net Income	8.2%	-24,602,000	-26,805,000	-25,054,000	-25,565,000	-26,288,000
Net Income Margin	24.5%	-47.15	-62.48	-91.03	-154	-608
Free Cashflow	-82.9%	-27,098,000	-14,815,000	-14,834,000	-24,350,000	-28,267,000

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	29.6%	596	460	493	494	197	201	148	136	162	168	182	199	211	223	77.00	88.00	96.00	18.00	11.00
Current Assets	29.2%	594	460	492	494	196	200	147	135	162	167	181	198	210	223	75.00	87.00	95.00	17.00	11.00
Cash Equivalents	25.5%	316	252	245	351	55.00	72.00	61.00	55.00	52.00	40.00	36.00	68.00	98.00	142	68.00	86.00	93.00	16.00	11.00
Net PPE	-20.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	20.2%	60.00	50.00	51.00	48.00	45.00	48.00	67.00	33.00	36.00	21.00	9.00	-	8.00	-	-	-	-	-	-
Current Liabilities	17.4%	30.00	25.00	26.00	24.00	25.00	34.00	27.00	18.00	20.00	20.00	8.00	8.00	8.00	9.00	7.00	8.00	6.00	23.00	4.00
Long Term Debt	0.6%	25.00	25.00	24.00	24.00	20.00	13.00	12.00	14.00	17.00	1.00	1.00	-	-	-	-	-	-	-	-
LT Debt, Current	-	-	-	-	-	-	7.00	8.00	5.00	3.00	-	-	-	-	-	-	-	-	-	-
LT Debt, Non Current	0.6%	25.00	25.00	24.00	24.00	20.00	13.00	12.00	14.00	17.00	1.00	1.00	-	-	-	-	-	-	-	-
Shareholder's Equity	30.7%	536	410	442	446	152	153	80.00	103	126	147	173	190	203	214	70.00	80.00	90.00	-	-
Retained Earnings	-9.6%	-457	-417	-382	-344	-315	-290	-263	-238	-213	-186	-158	-137	-123	-110	-95.91	-84.14	-73.60	-54.31	-16.18
Additional Paid-In Capital	20.0%	993	828	825	790	467	444	344	342	339	334	331	328	326	325	166	164	164	0.00	0.00
Shares Outstanding	22.2%	93.00	76.00	74.00	53.00	51.00	29.00	20.00	20.00	20.00	20.00	20.00	20.00	-	-	-	-	-	-	-
Float	-	-	-	1,176	-	-	-	30.00	-	-	-	166	-	-	-	72,707,052	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-13.0%	-34,293	-30,361	-34,447	-30,085	-27,096	-14,815	-14,835	-24,344	-28,240	-13,450	-20,109	-14,982	-14,028	-12,940	-11,524	-7,752	-11,132	-6,197	-3,964	-4,167	-
Share Based Compensation	-7.9%	4,037	4,381	4,137	3,551	2,758	2,500	2,586	2,512	2,154	2,314	2,417	1,793	1,250	1,154	910	493	166	112	76.00	35.00	-
Cashflow From Investing	-266.1%	-63,643	38,326	-101,808	4,106	-11,061	-42,058	-7,596	26,772	19,086	17,359	-13,876	-15,410	-29,028	-71,999	-5,744	-61.00	-111	-8.00	-18.00	-2.00	-
Cashflow From Financing	11057.5%	162,171	-1,480	30,766	321,654	21,011	68,631	28,160	29.00	21,891	72.00	1,692	216	-312	158,292	-65.00	9.00	88,377	488	-	-	-

ETNB Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 122,230	$ 80,796	$ 70,330
General and administrative	28,974	21,453	19,413
Total operating expenses	151,204	102,249	89,743
Loss from operations	(151,204)	(102,249)	(89,743)
Interest expense	(4,794)	(1,922)	(674)
Interest income and other, net	17,676	2,164	148
Net loss before income tax	(138,322)	(102,007)	(90,269)
Income tax (expense) benefit	(3,867)	(19)	147
Net loss	(142,189)	(102,026)	(90,122)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	547	(299)	(71)
Foreign currency translation adjustments	(7)	13	17
Total other comprehensive income (loss)	540	(286)	(54)
Comprehensive loss	$ (141,649)	$ (102,312)	$ (90,176)
Net loss per share, basic	$ (2)	$ (2.93)	$ (4.48)
Net loss per share, diluted	$ (2)	$ (2.93)	$ (4.48)
Weighted-average shares used to compute net loss per share, basic	71,172,870	34,806,349	20,098,340
Weighted-average shares used to compute net loss per share, diluted	71,172,870	34,806,349	20,098,340

ETNB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 316,161	$ 55,255
Marketable securities	262,709	132,905
Prepaid and other current assets	14,664	7,920
Total current assets	593,534	196,080
Operating lease right-of-use assets	2,293	363
Property and equipment, net	46	92
Other assets	396	289
Total assets	596,269	196,824
Current liabilities:
Accounts payable	8,585	12,502
Accrued expenses	20,530	11,944
Operating lease liabilities, current	496	168
Total current liabilities	29,611	24,614
Operating lease liabilities, non-current	1,817	186
Term loan, non-current, net	24,795	20,192
Other non-current liabilities	3,740
Total liabilities	59,963	44,992
Commitments and contingencies (Note 5)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized, none issued and outstanding
Common stock, $0.001 par value; 200,000,000 and 100,000,000 shares authorized and 93,269,377 and 50,560,590 shares issued and outstanding as of December 31, 2023 and 2022, respectively	93	51
Additional paid-in capital	993,455	467,374
Accumulated other comprehensive income (loss)	190	(350)
Accumulated deficit	(457,432)	(315,243)
Total stockholders’ equity	536,306	151,832
Total liabilities and stockholders’ equity	$ 596,269	$ 196,824

About 89bio Inc

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The company's lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis; and for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

CEO	Mr. Rohan Palekar
WEBSITE	89bio.com
INDUSTRY	Biotechnology
EMPLOYEES	45

89bio Inc Frequently Asked Questions

What is the ticker symbol for 89bio Inc? What does ETNB stand for in stocks?

ETNB is the stock ticker symbol of 89bio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of 89bio Inc (ETNB)?

As of Fri Apr 19 2024, market cap of 89bio Inc is 848.99 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ETNB stock?

You can check ETNB's fair value in chart for subscribers.

What is the fair value of ETNB stock?

You can check ETNB's fair value in chart for subscribers. The fair value of 89bio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of 89bio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ETNB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is 89bio Inc a good stock to buy?

The fair value guage provides a quick view whether ETNB is over valued or under valued. Whether 89bio Inc is cheap or expensive depends on the assumptions which impact 89bio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ETNB.

What is 89bio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 19 2024, ETNB's PE ratio (Price to Earnings) is -5.97 and Price to Sales (PS) ratio is 545.28. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ETNB PE ratio will change depending on the future growth rate expectations of investors.